Ascendis Pharma A/S (ASND) Scheduled to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) will be announcing its earnings results on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million for the quarter, compared to the consensus estimate of $97.02 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Up 1.9 %

ASND opened at $144.83 on Wednesday. The company’s fifty day moving average price is $149.15 and its two-hundred day moving average price is $125.48. Ascendis Pharma A/S has a 1-year low of $66.03 and a 1-year high of $161.00. The company has a market cap of $8.43 billion, a price-to-earnings ratio of -15.66 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ASND. Morgan Stanley reiterated an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a report on Monday. Cantor Fitzgerald reiterated an “overweight” rating and issued a $173.00 target price on shares of Ascendis Pharma A/S in a report on Thursday, April 18th. Wedbush increased their price target on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research report on Thursday, February 8th. JPMorgan Chase & Co. increased their price target on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research report on Tuesday, April 2nd. Finally, Wells Fargo & Company increased their price target on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a research report on Friday, March 15th. Two research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $173.25.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.